INCUBATORS IGNITING BIOSCIENCE ECOSYSTEM
Incubators and accelerators are driving small and medium enterprises (SMEs) in Asia
through the development of novel therapeutics and encouraging innovations and
commercialisation. Biotechnology incubators provide a stimulating environment that
attracts investors, talent, and companies to collaborate on research, thereby fostering
industry growth. While the appetite for laboratory space is constantly growing among
biotech ventures, countries in the Asia Pacific (APAC) region are actively investing
to construct life science hubs that foster innovation strategies and strengthen R&D
capabilities. Let’s explore prominent startup incubators and accelerators in key APAC
economies that are cultivating biotech innovations to create unicorns.

APAC takes Centre stage in AI-Driven Drug Discovery
The Asia-Pacific (APAC) region is rapidly emerging as a leader in AI-driven drug discovery, fuelled by robust research ecosystems and strong industry collaboration. Substantial investments, cutting-edge technologies, and strategic partnerships are optimising drug development efficiency. As Artificial Intelligence (AI) has become more embedded into many facets of everyday life, it has become an indispensable part of the drug discovery landscape. 2024 was the year of reckoning when AI in drug discovery received the highest validation—three researchers who leveraged the neural network AI programme AlphaFold to predict protein structures won the Nobel Prize in Chemistry. The industry is pushing ahead, using tech to make the business of drug development faster, safer, and more economical. Morgan Stanley estimates that AI's use in drug development could lead to 50 more successful treatments over a decade, potentially creating a $50 billion market.

BioSpectrum Asia Excellence Awards 2024
Honouring Innovators in Asia's Thriving Life Sciences Sector
Asia has, indeed, become the new hub for growth and innovation, with no signs of losing steam. To recognise the Asian companies and individuals for their commendable performance and achievements during 2023 and 2024, BioSpectrum Asia Excellence Awards 2024 ceremony was held at Hotel Fort Canning in Singapore on December 6, 2024.

2025 Trends 
Buoying Boom 
Phase in APAC
 Like many industries, life sciences, too, faced numerous challenges in 2024, such as a 
slowing economy, and geopolitical conflicts. Despite these headwinds, the sector has 
shown remarkable resilience, with strong prospects for recovery and growth. Significant 
investments are being directed toward research and development in key areas such as 
Antibody Drug Conjugates (ADCs), Cell and Gene Therapies, Artificial Intelligence (AI) and 
Contract Development and Manufacturing Organisations (CDMOs) and many more. These 
f
 ields have been major drivers of growth this year and offer promising opportunities. It’s 
that time of year again when we interact with leaders from major market segments of the 
industry. These leaders provide their insights into what the coming year is likely to hold for 
their respective fields. Lets look into a few trends from life sciences that are expected to 
make a significant splash in 2025

APAC Bullish on Biosupplier Revenue  
Amidst Global Uncertainty The Asia-Pacific (APAC) market plays a 
crucial role for global biosupplier companies, contributing anywhere from 15 per cent to 25 per cent of their total global revenues. Between 2021  and 2023, the bioprocessing market was one of the strongest performers, growing at about 18 per cent  annually due to COVID-19-driven demand. However,2023 was a challenging year for biosuppliers, with  the decline in COVID-19-related spending and various global events impacting business, resulting  in plummeting revenue for most firms.
While the bioprocessing sector saw impressive growth between 2021 and 2022, post-COVID-19 normalisation and rising financing costs have led to  flat growth from 2022 to 2023. Despite this, the market is expected to rebound over the next two years, with an average growth forecast of around 9 per cent from 2023 to 2027, according to a report from Clearstate.

How  alarming is Monkeypox Threat Perception?
As the world finally emerges from the grip of COVID-19, a new threat looms: Mpox 
(formerly known as Monkeypox). In August 2024, the World Health Organisation (WHO) declared Mpox a global health emergency due to the rising cases of the new strain, clade I Mpox in Africa and Sweden, underscoring the urgent need for coordinated global action to monitor and contain the virus. As of September 2024, 2082 confirmed Mpox cases were reported globally, marking the highest number of monthly cases globally since November 2022. Nearly 400 cases have been reported in Asia Pacific this year.How are Asia Pacific countries stepping up surveillance measures and preparing their healthcare systems to combat Mpox? And just how significant is the threat posed by this outbreak?

Rebooting Japan’s Biotech Growth Engine
Japan was once a global leader in life sciences innovation, responsible for nearly 30 per cent of all new drugs. However, its share has since dropped to less than 10 per cent. Between 1995 and 2018, Japan's contribution to the global pharmaceutical industry's valueadded declined by 70 per cent, from 18.5 to 5.5 per cent. Factors such  as strict price controls, reduced government investment in basic research, weak collaboration between industry and universities, and a slow regulatory process have significantly contributed to the decline in Japan's biopharmaceutical competitiveness, as noted in a 2022 paper by the Centre for Life Sciences 
Innovation, part of the Information Technology and Innovation Foundation, US. Japanese companies’ share of clinical trials also declined from 11 per cent in 2013 to 4 per cent in 2023. An IQVIA report found that the number of trials initiated by Japanese companies dropped from 501 in 2013 to 244 a decade later. Additionally, Japan launched only 20 new medicines in 2023, the lowest total since 2014, trailing behind the US and other major markets. Recognising this, the Japanese government 
has announced several initiatives designed to reshape the country’s biopharma ecosystem. These efforts include substantial increases in capital for venture funds, 
targeted subsidies for therapeutic drug development, and a suite of tax incentives aimed at empowering investors, entrepreneurs, and startup employees.

Addressing Root Causes of Brain Disorders with Innovative Therapeutics 

Neuroscience is a complex market encompassing a range of neurological conditions. Drug research and development for diseases related to the nervous system has always been challenging. While the oncology sector has seen remarkable progress with new therapies, neuroscience has historically lagged in providing effective cures or treatments for symptoms. However, there is now promising progress in understanding the intricate biology of these conditions and identifying new drug targets. A wave of novel late-stage candidates is advancing through the development pipeline, offering hope for treating serious Central Nervous System (CNS) disorders and entering the market. Recent high-profile approvals, such as Eisai's Leqembi for Alzheimer’s and Eli Lilly's Kisunla (donanemab-azbt) for the same condition, have significantly bolstered the morale of firms dedicated to developing neurological treatments. The neuroscience sector is suddenly back in action, with pharma companies renewing their interest, spurred by recent US FDA approvals in neurodegenerative diseases like Alzheimer’s. This renewed focus has catapulted neuroscience into one of the most sought-after areas.

Innovation Takes Centre Stage in Paediatric healthcare
Children represent approximately one-third of the world's population, with over 580 million  in the East Asia and Pacific region alone (Source: UNICEF). Historically underrepresented in healthcare care delivery and innovation, the landscape is evolving as governments and healthcare organisations in the region strive to address paediatric healthcare needs. Paediatric healthcare spans recommended immunisations before adulthood to developmental health, mental health, neonatal care and rare diseases, among others. Let’s deep dive into the innovations enhancing children’s well being in the region.

IPO FEVER GRIPS BIOTECH  INDUSTRY
After two tumultuous years marred by geopolitical tensions and recession, the biotech 
sector IPOs (initial public offering) is showing signs of recovery. Experts are hopeful 
that this year will revive the public equity markets for biotech companies. Twelve 
biotech companies have gone public this year, raising a total of nearly $1.5 billion, 
compared to a total of only nineteen biotech companies, throughout 2023. Are biotech IPOs poised for an upswing? Is the worst finally over for biotech IPOs? Let's find out.

What’s APAC’s Recipe of Success in CLINICAL TRIALS MARKET?
Asia-Pacific (APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world (RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Let's delve into the thriving clinical research landscape in the region and explore the trends driving its growth.

Addressing Accessibility and Affordability of CELL & GENE THERAPIES 
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry. Quite a few companies in the field are making remarkable advancements toward potentially curative treatments for challenging diseases using groundbreaking science. With lower R&D development costs than in advanced markets, China is becoming an attractive market for the development of CGT, and therefore may emerge as a strong competitor of overseas-made CGT, notes a 
GlobalData report. Bayer AG, recently announced the global expansion of its life science incubator network, Bayer Co. Lab, to Shanghai, China and Kobe, Japan. The new site in China will focus on oncology and CGT innovations. While India lags behind China in the production of cell and gene therapies, a wave of new biotech startups is emerging to address this challenge. Immuneel Therapeutics and ImmunoACT are currently developing CAR-T cell therapies. The latter’s  NexCAR19 therapy received approval from India's Central Drug Standards Control organisation (CDSCO) for treating relapsed or refractory B-cell lymphomas and leukaemia. Despite a steady stream of regulatory approvals and promising  growth prospects, the high manufacturing costs associated with these therapies often render them inaccessible to the majority of patients. To address this issue, companies are actively striving to streamline and optimise the highly intricate and labour-intensive process of cell and gene therapy manufacturing.

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
We are celebrating International Women's Day this time around by spotlighting women's roles and challenges in life sciences, spanning leadership, clinical trials participation and pay parity issues. Section I of the story highlights remarkable women leading public sector organisations in life sciences in APAC. Section II discusses the persistent issue of pay parity in the sector, while the final section tackles issues related to women in clinical trials. Let's delve deeper.

Next-Gen ADCs as Precision Weapon Against Cancer
Antibody-Drug Conjugates (ADCs) are emerging as a crucial frontier in targeted cancer care. Although the first ADC was approved in 2000, the space has experienced a renaissance in recent times. Major pharmaceutical players like Novartis and Pfizer, including startups, are announcing deals in this space almost every day. Within the Asia-Pacific (APAC) region, China stands at the forefront of ADC drug development. GlobalData reports that numerous domestic companies in China are actively shifting their focus towards the creation of pioneering ADC-based treatment options, particularly for solid tumours like breast, gastric, and bladder
cancer. When we observe World Cancer Day on February 4, we explore the promising world of next-gen ADCs, exploring advancements and unravelling the advantages they offer compared to other therapies like cell and gene therapies.

Transformative Life Sciences Trends for 2024
The intersection of tech and healthcare holds immense potential for the life sciences industry. From generative artificial intelligence (GenAI), augmented reality (AR), and virtual reality (VR) to decentralised clinical trials and 3D printing, we delve into the latest tech trends such Cellular Multi-Omics, Gene Editing CRISPR Technologies, Decentralised Clinical Trial (DCTs), digital health, digital twins, smart manufacturing, and wearables poised to lead the life sciences landscape in 2024.

Buoyant Life Sciences Sector Emerges Stronger
As we bid farewell to another eventful year in the world of life sciences, it’s time to look back at the whirlwind of advancements and changes that have shaped the industry in 2023. Back in January this year, we interacted with leaders from various market segments who shared their insights into what the year held for their particular spheres. Let’s recap the 2023 predictions and find out if they panned out as predicted.

Addressing Diabetes-related  complications 
Southeast Asia is currently home to 90 million adults diagnosed with diabetes, and this number is expected to reach 113 million by 2030, according to the International Diabetes Federation (IDF) Diabetes Atlas 2022. Out of these 90 million, 46 million remain undiagnosed. The delayed diagnosis of diabetes leads to prolonged periods of uncontrolled  hyperglycemia, resulting in severe diabetes related complications, such as diabetic retinopathy (eye problems), diabetic foot ulcers (DFU), diabetic nephropathy (kidney problems), and cardiovascular diseases. The vast number of people affected by diabetes, including many who are undiagnosed or at risk, presents a massive market for innovative treatments and preventive solutions. New technologies and novel treatment approaches offer hope for better prevention and management of these diabetes-related complications.

Big Pharma Sets Sights on Middle East
The Middle East, traditionally renowned for its prominence in the travel and oil and gas industries, is shifting its focus towards the life sciences sector. The region is actively forging numerous partnerships, initiatives, and programmes, and spending billions to establish itself as a major hub for life sciences. As the population of the region continues to grow and age, there is a clear and growing demand for locally manufactured medical treatments and products. Big pharma players are also making substantial inroads into the Middle East, with the Kingdom of Saudi Arabia (KSA), 
Qatar, and the United Arab Emirates (UAE) leading the way in these regional efforts. Areas such as rare diseases, genomics, personalised medicines, and pharmaceutical manufacturing have emerged as hotspots in the Middle East. Let’s delve deeper 
into the region’s endeavours to become a biotech powerhouse.

Multipronged Approach Against Alzheimer’s Disease
In July 2023, Eisai and Biogen received full traditional approval from the United States Food and Drug Administration (US FDA) for their Alzheimer’s drug Leqembi (lecanemab-irmb). This drug is the first to target the disease’s progression rather than merely addressing its symptoms. The approval has infused excitement and hope into the field of Alzheimer’s drug development, known for frequent drug failures. Alzheimer’s Disease (AD) is an escalating global health crisis. In 2020, the World Health Organisation (WHO) noted over 50 million people had dementia worldwide; 60 per cent of them lived in low- to middle-income countries. The Asia Pacific region bears a hefty burden with dementia care costs at $185 billion, straining healthcare in populous economies, according to ADI (Alzheimer’s Disease International). As we mark World Alzheimer’s Day this year on September 21, let’s take a stock of the advancements in the research and development in the Asia Pacific.

TAIWAN BIOMED INDUSTRY EYES $32B 
Biomedicine is a top priority for Taiwan, with the government aiming to position the country as the leading hub for biomedical research and development in the Asia-Pacific region. By 2025, Taiwan aims to create 20 new medicines, introduce 80 high-value medical devices to the market, and elevate the biomedicine industry into a trillion-NT-dollar (approximately $32 billion) sector. The government has taken various initiatives, established biomedicines clusters and tweaked policies to achieve this goal. Has the effort paid off? How far has the country come to achieve its goals?

TECH-POWERED WAR ON AMR
The consistent increase in antimicrobial resistance (AMR) is threatening to undo many of the gains of modern medicine. The situation is particularly alarming in the Asia Pacific region, which could witness around 50 per cent of global annual AMR-related mortality by 2050. Around 62 per cent of antibiotics in the region are used without prescriptions, indicating inappropriate usage and significantly increasing
the risk of AMR strain emergence, according to a report from LEK Consulting Group. All this makes the region an epicentre of AMR and its consequences. In response to the growing threat, countries in the region have taken steps to tackle the AMR threat. These include a National Action Plan on AMR (NAP-AMR), antimicrobial stewardship efforts, diagnostics surveillance etc. However, the million-dollar
question is whether these steps will be effective and enough. Let’s find out.

TAPPING FULL POTENTIAL OF NANOPARTICLES
Nanoparticles are another powerful tool in the biotech industry’s arsenal for targeted drug delivery. Their extremely small size, measured in nanometres, makes them highly effective carriers for therapeutic agents. These miniature carriers can be customised to encase drugs, benefiting from their biocompatibility, controlled release capabilities, stability, and low toxicity. The precision offered by nanoparticles opens up a world of possibilities for treating various diseases, including infectious diseases, cancer, and neurological disorders. These tiny particles offer tremendous
potential for targeted drug delivery, enhanced therapeutic efficacy and precise disease targeting. Moreover, the global market for nanoparticle drug delivery is projected to grow significantly, reaching $123.6 billion by 2025, according to BCC Research. Let’s deep dive into the fascinating field of nanomedicines, advancements and challenges in nanoparticle drug delivery.

$15B Pharma R&D Spends ROCKS APAC
Earlier seen as a generic powerhouse, Asia is now an important hub for pharma R&D innovation. The total gross expenditure by major companies on R&D across the Asia Pacific region crossed the $15 billion mark (approx) in 2022. Oncology, neurology, and immunology continue to draw a significant chunk of this investment. BioSpectrum Asia examines how top pharma companies in the region are
allocating their R&D budgets and the impact of the ensuing R&D endeavours on the industry.

A World Sans MALARIA
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people. According to a latest report on malaria from the World Health Organisation (WHO), there were approximately 5.4 million cases and 9000 deaths in the region in 2021. The SEA region has nine countries where malaria is prevalent, and their contribution to the global burden of malaria cases is two per cent. India is the main contributor to the malaria cases in the region, accounting for 82.5 per cent of them, followed by Indonesia with 15.6 per cent, and Myanmar with 1.6 per cent. These three countries were responsible for almost all of the malaria cases in the region, making up 99.7 per cent of the total estimated cases. Governments, healthcare organisations, and communities are implementing innovative strategies, technologies, and programmes that can help curb the spread of malaria. Though these efforts were hampered because of COVID-19, in 2022, the WHO South-East Asia Region renewed its commitment to eliminate malaria by 2030, with countries pledging accelerated action and greater efforts at the sub-national and community levels. Other parts of Asia also progressed well. China was declared Malaria free in June 2021, after 70 years of fighting. In its fights against malaria, Asian countries have recently
announced significant investment including a $1.9 million investment in February 2023 by Japan’s GHIT Fund for the research and development of a new malaria drug, and a $1 million contribution by Singapore’s Ministry of Health to the Global Fund to fight AIDS, TB, and Malaria, announced in December 2022. While observing World Malaria day on April 25, let’s explore the current status of Asia’s malaria elimination efforts, highlighting the progress made and strategies needed for a malaria-free future.

HOW PLAUSIBLE IS ENDINGHOW PLAUSIBLE IS ENDING TB SCOURGE?
Tuberculosis (TB) has been the leading cause of death from a single infectious agent, ranking above HIV/AIDS for a long time. And, presently, Asia Pacific is right in the thick of it. South-eastern Asia (SEA) is home to 26 per cent of the world’s population with a 43 per cent burden of TB incidence, according to the World Health Organisation’s (WHO) global TB report 2021. Over the last three years, countries around the world, including in Asia and the Pacific, have faced double pandemics –COVID-19 and TB. Unfortunately, during this time, progress toward TB elimination stalled and, in some cases, reversed. COVID-19 made it harder for people to access TB diagnostics and care, eading to increases in cases and deaths since 2019. Four countries, India, Indonesia, the Philippines, and Myanmar accounted for most of the estimated increase in TB deaths, globally, in 2021. Not all is lost though. The countries in the region, especially India and Indonesia, have renewed their efforts to eliminate TB. India launched the TB Free India campaign – a plan to eliminate tuberculosis by 2025, five years ahead of the target set by the UN’s sustainable development goals. Indonesia received a $300 million loan from the World Bank to improve overage, quality and efficiency of TB response in the country. When observing World TB day this year on March 24, let’s take stock of the progress made by Asian countries in eliminating this dreaded disease and the way forward.

CANCER THERAPEUTICS GAINING GROUND IN APAC
Cancer, the leading cause of death in most parts of the world, is a veritable Achilles heel for the pharma industry. Not surprising that pharma companies continue to dedicate a significant part of their R&D budget for Oncology. Cancer medicine spending rose to $185 billion globally in 2021 and is expected to reach more than $300 billion by 2026, as per IQVIA. China’s oncology spending now exceeds the rest of emerging countries and is driven by expanded access to new therapies
and offset by lower prices. Chinese and other Asian cancer drug developers are at the forefront of driving innovation in this space. The focus of cancer treatment is rapidly shifting from a traditional one-size-fits-all approach to precision medicine, tailored treatments for individual patients. The next wave of innovations making headlines in the cancer space include immunotherapies, vaccines, CAR-T therapies, PD-1/L1 inhibitors, light-activated drugs etc. Many drug makers in Asia are investing in new science and hope to develop the next holy grail in oncology. Let’s take a deep
dive into the status of cancer drug research and development in the Asia Pacific (APAC).

Life Sciences Trends to Watch for in 2023
The past two years have been a rollercoaster ride for the global economy and the pharma industry hasn’t been impervious to the major financial upheavals either. Yes, it’s the Pandemic and Post-Pandemic world that’s been influencing people from all walks of life and industries, alike. Buzzwords notwithstanding, we do have to thank the pandemic situation that forced all stakeholders to innovate and pool the best and brightest resources to keep the Life Sciences industry thriving. While all other industries either lost steam in their growth plans, pharma boomed, not unlike the Phoenix rising from the ashes. It is this streak of resilience and growth that we want industry insiders to comment on. With curtains down for 2022, it’s time to look to the new year without the trepidation of the looming ‘Great Reset’. On an upbeat note, BioSpectrum brings you 23 trends and projections for 2023 that could reshape and influence our collective future.

BioSpectrum Asia Excellence Awards 2022 
Asia has, indeed, become the new hub for potential growth and innovation, with no signs of losing steam. To appreciate the Asian companies and individuals for their commendable performance and achievements during Calendar Year (CY) 2021, BioSpectrum Asia Excellence Awards 2022 ceremony was held at Lavender Ball Room, Hotel Fort Canning in Singapore on December 2, 2022. These awards are an extension to observe and highlight the winners in the long battle to tackle the world’s emerging health problems and find solutions. Since 2020 and 2021 were majorly affected by COVID-19, we saw the industry players relentlessly working towards developing novel solutions in the form of diagnostic tests, vaccines, monoclonal antibodies, drugs etc. to fight the emergency.

Invincible Diabetes Turns APAC Into Pharma Goldmine
There are over 235 million diabetic patients in Asia. China and India account for almost half of the world’s diabetic population. By 2030, without intervention, both China and India combined will have nearly half a billion diabetics. These are grim figures but for pharma firms, they represent a huge opportunity, and big pharma firms are spending billions in search of the next blockbuster drug for diabetes,
according to the estimates from Singapore-based Asian Diabetes Prevention Initiative (ADPI). The diabetes care drugs market is highly fragmented in Asia Pacific (APAC) region with a few major manufacturers gaining presence in major countries of the APAC market, while the remaining market comprises other local or regionspecific manufacturers. Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as drive innovations, helping the diabetes drugs market to increase in the APAC region. Let’s look at who owns the more significant piece of the pie and the competitive landscape of diabetes treatment in the region.

Can Technology Efface SLEEP DISORDERS?
The world is wide awake. Sleep disorders are on the rise globally and the Asia Pacific is no
different. There are numerous studies documenting how sleep loss is rampant and becoming an epidemic. Approximately 45 per cent of people worldwide don’t get enough sleep. Asians have the shortest average sleep time, according to researchers from Flinders University, Australia. To combat these, firms are now turning to technology. The emergence of wearables, smart devices, trackers, and patches has made widespread remote sleep monitoring possible. Insights gained from the data collected by these devices are used to improve understanding of sleep and create preventative sleep loss strategies. Let’s look at how healthcare firms are trying to unlock the science of sleep disorders diagnosis and treatment by leveraging new tech.

BioSpectrum Asia  Cover - BioSpectrum Asia Feb 2025 Edition

BioSpectrum Asia Feb 2025

BioSpectrum Asia  - BioSpectrum Asia Feb 2025

BioSpectrum Asia  Cover - BioSpectrum Asia  Jan 2025 Edition

BioSpectrum Asia  Jan 2025

BioSpectrum Asia  - BioSpectrum Asia  Jan 2025

BioSpectrum Asia  Cover - December 2024 Edition

December 2024

BioSpectrum Asia  - December 2024

BioSpectrum Asia  Cover - BioSpectrum Asia Nov 2024 Edition

BioSpectrum Asia Nov 2024

BioSpectrum Asia  - BioSpectrum Asia Nov 2024

BioSpectrum Asia  Cover - October 2024 Edition

October 2024

BioSpectrum Asia  - October 2024

BioSpectrum Asia  Cover - September 2024 Edition

September 2024

BioSpectrum Asia  - September 2024

BioSpectrum Asia  Cover - August 2024 Edition

August 2024

BioSpectrum Asia  - August 2024

BioSpectrum Asia  Cover - July 2024 Edition

July 2024

BioSpectrum Asia  - July 2024

BioSpectrum Asia  Cover - June 2024 Edition

June 2024

BioSpectrum Asia  - June 2024

BioSpectrum Asia  Cover - May 2024 Edition

May 2024

BioSpectrum Asia  - May 2024

BioSpectrum Asia  Cover - April 2024 Edition

April 2024

BioSpectrum Asia  - April 2024

BioSpectrum Asia  Cover - March 2024 Edition

March 2024

BioSpectrum Asia  - March 2024

BioSpectrum Asia  Cover - BioSpectrum Asia Feb 2024 Edition

BioSpectrum Asia Feb 2024

BioSpectrum Asia  - BioSpectrum Asia Feb 2024

BioSpectrum Asia  Cover - BioSpectrum Asia January 2024 Edition

BioSpectrum Asia January 2024

BioSpectrum Asia  - BioSpectrum Asia January 2024

BioSpectrum Asia  Cover - December 2023 Edition

December 2023

BioSpectrum Asia  - December 2023

BioSpectrum Asia  Cover - November 2023 Edition

November 2023

BioSpectrum Asia  - November 2023

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

1. Du godtar at bruken av Magzter.com, applikasjonen og dens tjenester er på egen risiko. Verken Magzter.com eller dets samarbeidspartnere eller ansatte eller tredjeparts innholdsleverandører garanterer at tjenesten vil være fullstendig uavbrutt eller feilfri eller vanntett mot ondsinnede aktiviteter. De garanterer heller ikke at du vil få de nøyaktige resultatene som forventet eller lovet av nettstedet eller produktet.

11. TJENESTEN OG ALLE PUBLIKASJONER LEVERES PÅ EN «SOM DEN ER»- OG «SOM TILGJENGELIG»-BASIS. MAGZTER, DETS TILKNYTTEDE SELSKAPER, LEVERANDØRER, LISENSGIVERE OG AGENTER FRASKRIVER SEG UTTRYKKELIG ALLE GARANTIER AV ENHVER SLAG, ENTEN UTTRYKKELIGE ELLER IMPLISITTE, INKLUDERT MEN IKKE BEGRENSET TIL DE IMPLISITTE SELGERGARANTIENE, EGNETHET FOR SPESIFIKKE FORMÅL OG IKKE-KRENKELSE. UTEN Å BEGRENSE DET OVENNEVNTE GARANTERER VERKEN MAGZTER ELLER DETS TILKNYTTEDE SELSKAPER, LEVERANDØRER, LISENSGIVERE ELLER AGENTER AT (I) TJENESTEN VIL INNFRI DINE KRAV, (II) TJENESTEN VIL VÆRE UFORSTYRRET, RETTIDIG, SIKKER ELLER FEILFRI (III) INFORMASJONEN SOM KAN FÅS FRA BRUKEN AV TJENESTEN ELLER SOM KAN VÆRE I PUBLIKASJONENE VIL VÆRE NØYAKTIG ELLER PÅLITELIG, ELLER (IV) KVALITETEN PÅ EVENTUELLE PUBLIKASJONER ELLER TJENESTEN VIL INNFRI DINE FORVENTNINGER. DU ER ALENE ANSVARLIG FOR Å SKAFFE OG VEDLIKEHOLDE EN PÅLITELIG INTERNETTILKOBLING OG ENHETEN DIN. MAGZTER ER IKKE ANSVARLIG FOR DIN MANGLENDE EVNE TIL Å LASTE NED INNHOLD. ALT MATERIALE SOM LASTES NED ELLER PÅ ANNEN MÅTE FÅS VIA BRUK AV TJENESTEN, GJØRES PÅ DITT EGET ANSVAR OG DIN EGEN RISIKO, OG DU STÅR ALENE ANSVARLIG FOR EVENTUELLE SKADER PÅ DITT DATASYSTEM ELLER DIN MOBILE ENHET ELLER TAP AV DATA SOM OPPSTÅR FRA NEDLASTING AV SLIKT MATERIALE. INGEN RÅD ELLER INFORMASJON, VERKEN MUNTLIG ELLER SKRIFTLIG, FÅTT AV DEG FRA MAGZTER ELLER VIA ELLER FRA TJENESTEN SKAL UTGJØRE NOEN FORM FOR GARANTI.

2. Du skal vedlikeholde og umiddelbart oppdatere denne informasjonen for å holde den sann, nøyaktig, oppdatert og fullstendig. Du er ansvarlig for å opprettholde konfidensialiteten til kontoen din og passordet ditt, for å begrense tilgangen til datamaskinen din, og du godtar ansvaret for all aktivitet som skjer på kontoen din, inkludert valg og bruk av alt innhold og tjenester.

3. Under ingen omstendigheter vil Magzter.com eller noen person eller enhet eller tredjepart som er involvert i opprettelsen, produksjonen og distribusjonen av innholdet på nettstedet og applikasjonen være ansvarlig i kontrakt eller juridisk for eventuelle skader, inkludert og ikke begrenset til, direkte, indirekte, vilkårlige, spesielle og følgevirkninger som påføres deg mens du bruker Magzter.com. Ved å registrere deg på nettsiden eller laste ned applikasjonen godtar du at bestemmelsene nevnt i denne delen skal gjelde for all bruk av og innhold på nettsiden og applikasjonen.

3. Uten skriftlig eller autorisert tillatelse fra Magzter på forhånd, må du ikke modifisere, kopiere, distribuere eller selge noe innhold hentet fra Magzter, for alt publisert her tilhører Magzter eller dets lisensgivere. Siden slik uautorisert bruk også kan bryte gjeldende lovverk, inkludert lover om opphavsrett og varemerker, forbyr Magzter dette på det sterkeste og vil avslutte tilgangen din og slette kontoen din hvis slik ulovlig aktivitet blir bevist eller oppdaget. Du blir også holdt ansvarlig for skader forårsaket av disse uautoriserte aktivitetene. Med unntak av det som er tillatt av utgivelsens lovlige eier, erkjenner du at du ikke får noen eierskapsrettigheter ved å laste ned utgivelser som du får tilgang til via tjenesten. Med unntak av det som er eksplisitt påkrevd i henhold til lov om opphavsrett eller tillatt av funksjonene i tjenesten, kan du ikke modifisere, reversere, publisere, overføre, vise, delta i overføringen eller salget av, lage avledede verk av, eller på noen måte kommersielt utnytte eller levere innholdet i appen, utgivelsene eller deler av dem til en tredjepart uten uttrykkelig tillatelse fra Magzter og eieren av slikt innhold. Vi gir deg ingen lisenser, uttrykt eller implisitt, for de immaterielle eiendelene til Magzter eller Magzters lisensgivere.

5. Du erkjenner spesifikt at Magzter.com ikke er ansvarlig for noen form for ærekrenkende eller støtende eller ulovlig oppførsel fra andre brukere eller tredjeparter eller deres innhold, og at risikoen for skade fra det ovennevnte ligger helt hos deg.

8. Magzter forbeholder seg alle rettigheter til å overvåke innholdet som publiseres og legges inn av deg for å avgjøre om du er i samsvar med disse vilkårene og betingelsene og andre driftsregler fastsatt av Magzter. Magzter har rett til å ta beslutninger om innholdet og slette dem etter eget forgodtbefinnende.

9. Magzter er distributør og IKKE utgiver av publikasjonene, og Magzter har derfor ingen redaksjonell kontroll over innholdet, inkludert meninger, råd, uttalelser, tjenester, tilbud osv., som er representert i magasinene. Magzter vil ikke ta ansvar for nøyaktigheten eller påliteligheten for informasjon eller fakta gitt deri eller som er gjort tilgjengelig gjennom tjenesten, av andre enn autoriserte Magzter-ansatte som handler i henhold til deres offisielle embete. Følgelig har vi ingen redaksjonell kontroll over publikasjonene. Eventuelle meninger, råd, uttalelser, tjenester, tilbud eller annen informasjon eller innhold uttrykt eller gjort tilgjengelig av tredjeparter, inkludert de som er gjort i publikasjoner som tilbys av tjenesten, tilhører sine respektive forfattere eller utgivere og ikke Magzter. Magzter vil ikke være ansvarlig for tap eller skade forårsaket av at du stoler på informasjon innhentet gjennom tjenesten eller fra publikasjonene. Tjenesten kan inneholde koblinger til andre internettsider og tredjepartsressurser, og Magzter påtar seg ikke noe ansvar for kommunikasjon eller materiale som er tilgjengelig på slike nettsteder via koblinger. Disse koblingene er kun for din bekvemmelighet. Du er alene ansvarlig for å forstå eventuelle vilkår og betingelser som kan gjelde når du besøker eller legger inn en bestilling gjennom en tredjepartsside.

Detaljer om det støtende innholdet, inkludert koblingen dens på plattformen vår

Last ned favorittitlene dine og les dem offline, når og hvor som helst

Gi dine kjære et Magzter-gavekort umiddelbart og gi dem friheten til å lese favorittmagasinene og -avisene sine fra tusenvis av bestselgende titler.

Gi dine kjære et Magzter-gavekort umiddelbart og gi dem friheten til å lese favorittmagasinene sine fra tusenvis av bestselgende titler.

Gi dine kjære et Magzter-gavekort umiddelbart og gi dem friheten til å lese favorittmagasinene sine blant {{magCount}} bestselgende internasjonale titler.

Girish Ramdas er medgründer og administrerende direktør for Magzter, en New York-basert oppstartsbedrift som har laget oppstyr i den globale digitale publiseringsvirksomheten. Magzter har nådd 80 millioner brukere siden oppstarten i 2011 fra mer enn 150+ land med tusenvis av magasiner, aviser og bøker fra mer enn 4500 utgivere over hele verden. Han har mer enn 25 års erfaring innen publisering på tvers av plattformer, inkludert trykk-, mobil- og webutvikling. I løpet av denne perioden har han vært med å grunnlegge og drive tre vellykkede oppstartsbedrifter. Han har gjort det mulig for magasinbedrifter å bli digitale og hjelper dem med å tjene penger på innholdet i den digitale verden. Girish' omfattende bransjeerfaring innen nett-, mobil- og publiseringsøkosystemer har gjort ham til en ekspert på anskaffelse, markedsføring og inntektsgenerering av digitalt innhold på tvers av globale plattformer.

I tilfelle du kommer over støtende innhold på plattformen vår, har vi innført retningslinjer for klagehåndtering for å behandle henvendelsene dine.

Magzter Inc. («bedrift», «vi», «oss» eller «vår/våre») vet at du bryr deg om hvordan personopplysningene dine brukes og deles. Les følgende personvernregler («retningslinjer») for å lære mer om personvernpraksisen vår. Ved å besøke noen av nettstedene som drives av selskapet, og eventuelle underdomener derav, eller ved å bruke noen av våre mobilapper og andre metoder for innholdsdistribusjon (samlet omtalt som «tjeneste»), erkjenner du at du godtar praksisen og retningslinjene skissert i disse retningslinjene, og du samtykker herved til at vi samler inn, bruker og deler informasjonen din på følgende måter.

Magzter Inc. er verdens største og raskest voksende selvbetjente digitale aviskiosk på tvers av plattformer med over 80 millioner brukere siden oppstarten i 2011 og med tusenvis av magasiner og aviser på tvers av 40+ kategorier og 60+ språk. Med hovedkontor i New York, har Magzter lokal tilstedeværelse i Amsterdam, London, Mexico by, Chennai, Mumbai, New Delhi, Bengaluru og Singapore, og vi vil snart utvide til andre land. Magzter ble grunnlagt av de globale entreprenørene Girish Ramdas og Vijay Radhakrishnan i juni 2011, og gjør det mulig for magasin- og avisutgivere over hele verden å lage og levere digitale utgaver av titlene deres for globale forbrukere.

Magzter er forpliktet til å tilby en trygg og sikker plattform til våre brukere. Vær oppmerksom på at Magzter bare er en plattform der utgivere kan distribuere innholdet sitt. Vi kontrollerer eller støtter ikke innholdet som publiseres på plattformen vår. Vi kan ikke holdes ansvarlige for handlingene til våre utgivere eller deres innhold.

Magzter er ikke ansvarlig for å kompensere noen part som har lidd skade eller pådratt seg kostnader på grunn av innhold, eller deler av innholdet, som krenker deres rettigheter. Magzter er ikke ansvarlig for noen rettslige skritt i sivilrett for brudd på rettigheter forårsaket av innhold, eller deler av innholdet, som krenker rettighetene til en tredjepart.

Magzter tilbyr verdens største {{allyoucanread}} abonnementstjeneste kalt {{gold}}, som gir digitale lesere ubegrenset tilgang til 9000+ magasiner og aviser for en månedlig abonnementspris. Magzter har også det største antallet historier i verden med sin revolusjonerende ezRead 2.0-funksjon for appene sine, som lar smarttelefon- og mobilbrukere med små skjermer nyte magasininnhold slik det var ment å bli lest, med artikkeltekst som er lett å lese og med fantastiske videoer og bilder i høy oppløsning.

Magzter tilbyr verdens største «alt du kan lese»-abonnementstjeneste kalt Magzter GOLD som gir digitale lesere ubegrenset tilgang til 9000+ magasiner og aviser for en månedlig abonnementspris. Magzter har også verdens største antall historier revolusjonerende ezRead 2.0-funksjon for appene sine, som gjør det mulig for smarttelefonbrukere og mobilbrukere med små skjermer å nyte magasininnhold, med artikkeltekst som er lett å lese og ledsages av fantastiske videoer og bilder i høy oppløsning.

Navn

Merk: Dette vil bare dele omslaget og utgivelsesinformasjonen, men ikke innholdet.

Fyll ut dette skjemaet hvis du trenger hjelp til å publisere innholdet ditt på Magzter

Før Magzter var han president for Dot Com Infoway (DCI) og Galatta Media. Hans oppgaver inkluderte strategisk markedsføring, partnerskapsutvikling og inntektsgenerering av innhold globalt. DCI vokste fra et lite team på 3 i 2000 til 300 innen 2011 og drev med utvikling av web, programvare og apper for kunder over hele verden.

Siden vi lanserte har Magzter vært forpliktet til å samarbeide med globale organisasjoner for å tilby best mulig aviskiosk-teknologi og -service til kundene våre. Enten du ønsker å tilby magasinabonnement til kundedatabasen din eller bare ønsker å finne ut mer, er Magzter forpliktet til å hjelpe bedriften din å vokse. For å finne ut mer fyll ut spørreskjemaet nedenfor:

DMCA tillater oss å gjenopprette det fjernede innholdet hvis parten som sender inn det opprinnelige DMCA-varselet ikke går til rettssak mot deg innen ti virkedager etter å ha mottatt kopien av innsigelsen din.

Disse retningslinjene dekker selskapets behandling av personopplysninger («personopplysninger») og annen informasjon om deg og din datamaskin eller enhet som selskapet samler inn når du får tilgang til tjenesten. Vi kan samle inn personopplysninger fra deg, som forklart mer detaljert nedenfor, og vi bruker disse personopplysningene internt i forbindelse med tjenestene våre, inkludert for å tilpasse, tilby og forbedre våre produkter, tjenester, innhold og annonser, og for å tillate deg å sette opp en brukerkonto og profil, for å kontakte deg, for å oppfylle dine forespørsler om visse produkter og tjenester, og for å analysere hvordan du bruker tjenestene. I visse tilfeller kan vi også dele noen personopplysninger med tredjeparter, men bare som beskrevet i punkt 4.

Denne tittelen er inkludert i Magzter GOLD-abonnementet ditt

For å analysere kvaliteten på innholdet og gi passende tilbakemeldinger til utgivere

Vi har utpekt en klageansvarlig for å behandle eventuelle klager knyttet til støtende innhold.

Vi ber om at enhver klage relatert til støtende innhold sendes til klageansvarlig via e-post til den ovennevnte e-postadressen. Vi ber også om at du oppgir følgende detaljer når du sender inn en klage:

og appen som gir deg muligheten til å bestille, abonnere og motta levering av ulike magasiner, bøker, nyheter og magasin- og publikasjonsrelatert innhold (samlet kjent som «publikasjoner») og få disse digitale versjonene av publikasjonene levert til deg

c. Vi samler også inn informasjon knyttet til din bruk av applikasjonen for å gi personlige anbefalinger. Hvis du oppgir din brukertilgangen for tredjepartskontoer til oss, forstår du at noe innhold og/eller informasjon i disse kontoene («tredjeparts-kontoinformasjon») kan overføres til kontoen din hos oss hvis du godkjenner slike overføringer, og at tredjeparts-kontoinformasjon som sendes til tjenesten, dekkes av disse retningslinjene.

f. Med personopplysningene vi samler inn kan vi svare på dine forespørsler, forbedre produktene og tjenestene våre, tilpasse annonsene og innholdet du ser, og kommunisere med deg om nye produkter.

er verdens største og raskest voksende, selvbetjente digitale aviskiosk på tvers av plattformer med over 88 millioner brukere siden oppstarten i 2011 og tusenvis av magasiner og aviser på tvers av 40+ kategorier og 60+ språk. Med hovedkontor i New York, har Magzter sin lokale tilstedeværelse i Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, og vil snart utvide til andre land. Magzter ble grunnlagt av de globale gründerne Girish Ramdas og Vijay Radhakrishnan i juni 2011, og gjør det mulig for magasin- og avisutgivere over hele verden å lage og levere digitale utgaver av titlene deres til globale forbrukere.

n. Vi vil også bruke bruksinformasjon for å sikre at brukerne overholder våre bruksvilkår. For eksempel vil en brukers bruksinformasjon hjelpe oss med å bekrefte at en bruker bare laster ned magasiner eller annet innhold det tillatte antallet ganger eller til det tillatte antallet enheter.

som gir digitale lesere ubegrenset tilgang til 9000+ magasiner og aviser for en månedlig abonnementspris. Magzter har også det største antallet historier i verden med sin revolusjonerende ezRead 2.0-funksjon for appene sine, som lar smarttelefon- og mobilbrukere med små skjermer nyte magasininnhold slik det var ment å bli lest, med artikkeltekst som er lett å lese og med fantastiske videoer og bilder i høy oppløsning.

{{magzter}} er verdens største og raskest voksende, selvbetjente digitale aviskiosk på tvers av plattformer med over 88 millioner brukere siden oppstarten i 2011 og tusenvis av magasiner og aviser på tvers av 40+ kategorier og 60+ språk. Med hovedkontor i New York, har Magzter sin lokale tilstedeværelse i Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, og vil snart utvide til andre land. Magzter ble grunnlagt av de globale entreprenørene Girish Ramdas og Vijay Radhakrishnan i juni 2011, og gjør det mulig for magasin- og avisutgivere over hele verden å lage og levere digitale utgaver av titlene deres til globale forbrukere.

BioSpectrum Asia - September 2022

BioSpectrum Asia - September 2022

I denne utgaven

BioSpectrum Asia Magazine Description: